NCI, Otsuka's Inqovi and AbbVie's Venclexta Combination Therapy in Phase 2 AML Trial to Evaluate Shorter Treatment Duration
Expansion of All-Oral Combination Therapy and the MyeloMATCH Clinical Design
This Phase 2 trial (NCT07437950), part of the MyeloMATCH program led by the U.S. National Cancer Institute (NCI), focuses on older patients with acute myeloid leukemia (AML). Researchers aim to explore the optimal duration of Venclexta administration in the combination therapy of Inqovi (decitabine/cedazuridine) from Otsuka Holdings and Venclexta (venetoclax) from AbbVie. The study randomly assigns patients to either the standard 28-day regimen or a shortened 14-day regimen for comparative evaluation. This approach seeks to minimize the physical burden on older patients while maximizing treatment efficacy, aligning with precision medicine principles.
Synergy of BCL-2 and DNMT Inhibition Mechanisms and the Need for Toxicity Management
Inqovi is a combination drug containing decitabine and cedazuridine, which prevents the degradation of decitabine, enabling oral administration and significantly improving patient convenience. Combined with Venclexta, which induces apoptosis in cancer cells, this combination exhibits a strong synergistic effect in suppressing tumor cells. However, the combination of these two drugs can cause significant hematological toxicities, including neutropenia, requiring careful monitoring in clinical practice. Therefore, shortening the Venclexta administration period to 14 days has emerged as a strategy to prevent drug accumulation-related toxicity and promote the recovery of bone marrow function in patients.
Evaluation of Non-Inferiority and Superiority Based on Measurable Residual Disease (MRD)
The primary endpoint of this trial is the rate of measurable residual disease (MRD)-negative complete remission (CR) at 180 days after treatment initiation. Researchers first aim to demonstrate that the 14-day shortened administration group is not more than 12% less effective than the 28-day standard administration group, establishing non-inferiority. If non-inferiority is proven, the study will further evaluate whether the shortened administration group exhibits superiority by demonstrating a higher MRD-negative complete remission rate due to reduced toxicity and faster bone marrow recovery. This could represent a clinical milestone, potentially improving treatment efficacy beyond simply reducing side effects.
Paradigm Shift from Injectable to Oral Administration and Market Competition
The current standard of care for acute myeloid leukemia treatment is the combination of Vidaza (azacitidine) injection and Venclexta. However, the requirement for older patients to visit the hospital multiple times a month for injections has been a significant limitation. The all-oral combination of Inqovi and Venclexta is gaining attention as a powerful alternative that can overcome these limitations. With the global AML treatment market expected to grow to approximately $6.3 billion by 2030, the results of this trial are expected to accelerate the shift towards oral-based therapies.
With the global acute myeloid leukemia (AML) treatment market projected to reach approximately $6.3 billion by 2030, this Phase 2 trial represents an effort to establish optimized guidelines for all-oral treatment regimens. Compared to the current standard treatment of Vidaza injection and Venclexta, the oral combination of Inqovi and Venclexta has the potential to erode market share by improving treatment convenience for older patients. If the study demonstrates non-inferiority in terms of measurable residual disease (MRD)-negative complete remission rate compared to the 28-day standard administration group, while shortening Venclexta administration to 14 days to mitigate toxicity, it will lead to significant improvements in patient quality of life and reductions in healthcare costs. From an investor perspective, this represents an opportunity for Otsuka Holdings and AbbVie to expand their commercial reach, and whether the 12% non-inferiority margin is met will be a key indicator for progression to a Phase 3 trial and changes in prescribing patterns. From the perspective of researchers and the industry, the MyeloMATCH platform trial, which considers genetic heterogeneity, is expected to facilitate the development of personalized precision treatment protocols for older AML patients.
Source: ClinicalTrials.gov (api_ct)